Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
- Alffenaar, J.W.C.
- Laan, T. van der
- Simons, S.O.
- Werf, T.S. van der
- Kasteele, P.J. van de
- Neeling, H. de
- Soolingen, D. van
DOIAbstract
Item does not contain fulltextSusceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).1 maart 201
Add to ORKG